NCT03812666 (IBIS) is a clinical trial in Stroke, Acute, sponsored by Jakob Ström.

Who is sponsoring NCT03812666?

NCT03812666 is sponsored by Jakob Ström.

What condition does NCT03812666 study?

NCT03812666 studies Stroke, Acute, Pneumonia, Bacterial.

Is NCT03812666 still recruiting?

NCT03812666 is currently status unknown. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT03812666: IBIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Search for Biomarkers of Infection and Inflammation in Patients With Acute Stroke.

Status unknown Last updated 18 November 2023

What this trial tests

trial in Stroke, Acute in 200 participants. Status unknown.

Timeline

15 January 2019

Primary endpoint
1 July 2023

1 July 2025

Quick facts

Lead sponsor	Jakob Ström
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	15 January 2019
Primary completion	1 July 2023
Estimated completion	1 July 2025
Sites	1 location across Sweden

Conditions studied

Stroke, Acute — all drugs for Stroke, Acute →
Pneumonia, Bacterial — all drugs for Pneumonia, Bacterial →

Sponsor

Jakob Ström

Who can join

18 and older, any sex, with Stroke, Acute or Pneumonia, Bacterial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will look for new biomarkers of infection and evaluate current biomarkers of infection in stroke patients. Patients with acute stroke will be monitored with daily blood samples for seven days and by clinical examination to detect infections for 10 days.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in development of biomarkers for brain damage and ischemia.
Karimova D, Rostami E, Chubarev VN, Tarasov VV, et al · · 2024 · cited 5× · PMID 39001884 · DOI 10.1007/s11033-024-09708-x
Plasma Profiles of Neuroglial Injury Biomarkers after Ischemic Stroke.
Sjölin K, Röyter B, Forgo B, Aulin J, et al · · 2025 · cited 1× · PMID 40900222 · DOI 10.1007/s12975-025-01380-y

Verify or expand the search:

Other recruiting trials for Stroke, Acute

Currently open trials in the same condition.

NCT06825897 — Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiograp · NA · recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT07253870 — Comperative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation in Subacute Stroke Patients · NA · recruiting
NCT06941753 — Off-script Diagnosis & Differential Diagnosis (D&D) Training and Residents' Stroke Knowledge · NA · recruiting
NCT06123650 — Post Stroke Dysphagia: Effect of Adding rTMS to Conventional Therapy on the Prevalence of Pneumonia. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03812666 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jakob Ström
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03812666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing